Eli Lilly shares jump on two big updates and Jim Cramer is so here for it
The Biden administration proposed a rule change that would expand access to Eli Lilly's Zepbound. And an obesity drug competitor released disappointing results.
The Biden administration proposed a rule change that would expand access to Eli Lilly's Zepbound. And an obesity drug competitor released disappointing results.
